menu
    • menu
    [{"orgOrder":0,"company":"Argenx","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Nephrology","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ Zai Lab"},{"orgOrder":0,"company":"Argenx","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Nephrology","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ Zai Lab"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AM-Pharma

                            Netherlands arrow
                            AAPS
                            Not Confirmed

                            AM-Pharma

                            Netherlands arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ilofotase Alpha

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AM-Pharma Initiates Phase 2 Trial Of Ilofotase Alfa for Kidney Damage

                            Details : recAP (Ilofotase Alfa), a recombinant alkaline phosphatase, is in Phase 2 trials for cardiac surgery-associated renal damage.

                            Product Name : recAP

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            January 16, 2024

                            Lead Product(s) : Ilofotase Alpha

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Argenx

                            Netherlands arrow
                            AAPS
                            Not Confirmed

                            Argenx

                            Netherlands arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efgartigimod

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Zai Lab

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Lupus Nephritis (ZL-1103-0...

                            Details : Efgartigimod is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lupus Nephritis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 13, 2023

                            Lead Product(s) : Efgartigimod

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Zai Lab

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Argenx

                            Netherlands arrow
                            AAPS
                            Not Confirmed

                            Argenx

                            Netherlands arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efgartigimod

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Zai Lab

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephrop...

                            Details : Efgartigimod is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glomerulonephritis, Membranous.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 13, 2023

                            Lead Product(s) : Efgartigimod

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Zai Lab

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AM-Pharma

                            Netherlands arrow
                            AAPS
                            Not Confirmed

                            AM-Pharma

                            Netherlands arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ilofotase Alpha

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Cowen

                            Deal Size : $176.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            AM-Pharma Increases Funding To €163m For Phase-Iii Trial Of Recap In Sa-Aki

                            Details : New capital to be used to support a multi-national pivotal Phase III trial of recAP in 1,400 patients with sepsis-associated-acute kidney injury (SA-AKI).

                            Product Name : recAP

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            March 31, 2020

                            Lead Product(s) : Ilofotase Alpha

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Cowen

                            Deal Size : $176.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AM-Pharma

                            Netherlands arrow
                            AAPS
                            Not Confirmed

                            AM-Pharma

                            Netherlands arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Alkaline Phosphatase

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : PPD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI

                            Details : Recombinant Alkaline Phosphatase is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Acute Kidney Injury.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            July 08, 2014

                            Lead Product(s) : Recombinant Alkaline Phosphatase

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : PPD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth